RPAM
PLRX icon

Rhenman & Partners Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-116,250
Closed -$1.53M – 99
2024
Q4 		$1.53M Sell
116,250
-4,000
-3% -$54.6K 0.16% 84
2024
Q3 		$1.35M Hold
120,250
– – 0.11% 92
2024
Q2 		$1.29M Sell
120,250
-25,000
-17% -$322K 0.12% 86
2024
Q1 		$2.16M Buy
145,250
+32,509
+29% +$536K 0.21% 74
2023
Q4 		$2.04M Buy
+112,741
New +$1.71M 0.2% 73

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Rhenman & Partners Asset Management's PLRX Position: Q1 2025 in Review

Rhenman & Partners Asset Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 116,250 shares — an estimated $1.53M sold.

Rhenman & Partners Asset Management first reported a position in PLRX in Q4 2023 and held it in 5 quarters. The position peaked at $2.16M in Q1 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Rhenman & Partners Asset Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 116,250 Pliant Therapeutics shares in Q1 2025, an estimated $1.53M.
  • Rhenman & Partners Asset Management first reported a position in Pliant Therapeutics in Q4 2023 and held it in 5 quarters.
  • Rhenman & Partners Asset Management's Pliant Therapeutics position peaked at $2.16M in Q1 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.